THYROCAREBSEThyrocare Technologies LtdHighPositive
Announced Thu, 7 May · 19:44 IST

Please refer the enclosed the intimation letter

Director Flagged GovernanceManagement Changes View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.3%1-day move
₹472.50
prior close
₹493.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9
Up moveDown movePending
AI summary

Thyrocare's Board approved several key items including a final dividend of Rs. 7 per share for FY 2025-26 (total annual dividend Rs. 9.33 per share post-bonus). The company appointed Price Waterhouse Chartered Accountants LLP as new statutory auditors for a 5-year term, replacing M S K A & Associates upon completion of their term. CEO Rahul Franklin Guha was re-appointed for another 5 years (May 2027 to May 2032). Two Non-Executive Non-Independent Directors—Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah—resigned citing preoccupation and other commitments. Two new Additional Directors, Uday Patel Kadam and Gaurav Verma, both from API Holdings (parent company), were appointed. The Board also approved investing up to Rs. 5.5 crore in Think Health Diagnostics Private Limited, a wholly owned subsidiary, and proposed amendments to the Memorandum of Association to expand the company's healthcare and diagnostics business scope.

Likely market impact

The resignation of two directors coinciding with appointments from the parent company API Holdings suggests a shift in board composition and potential consolidation of control. Shareholders can expect continued focus on digital transformation and healthcare expansion, supported by the new auditor appointment.